Aardvark Therapeutics Inc. (AARD) has emerged as one of the most closely watched names in the biotech space, with its pipeline targeting obesity and rare genetic disorders. The company's recent clinical updates, strategic alignment with regulators, and strong cash position have set the stage for pivotal milestones in 2026 and beyond.
ARD-101: Expanding Reach in Prader-Willi Syndrome
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.